Clinical trial
To Investigate the Glycemic Control and Lipid Profile of CKD-501 Monotherapy in Patients With Type 2 Diabetes Mellitus:a Eight-week, Multicenter, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-ranging Study.
NCT01030679 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- To Investigate the Glycemic Control and Lipid Profile of CKD-501 Monotherapy in Patients With Type 2 Diabetes Mellitus:a Eight-week, Multicenter, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-ranging Study.
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- October 31, 2008
- Enrollment
- 214 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.